Published in Hepatology on May 01, 2003
The Effect of an RBAC Supplement (BRM4) on NAFLD | NCT02568787
Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH) | NCT00845845
Effect of Fatty Liver on TCA Cycle Flux and the Pentose Phosphate Pathway (HPFFF) | NCT03480594
Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98
Molecular mediators of hepatic steatosis and liver injury. J Clin Invest (2004) 9.40
Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci U S A (2003) 8.20
The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol (2006) 3.62
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55
The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (2009) 3.48
The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis (2010) 2.96
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab (2011) 2.75
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology (2010) 2.75
A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res (2009) 2.75
Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol (2007) 2.71
Nonalcoholic fatty liver disease. CMAJ (2005) 2.56
Pathogenesis of non-alcoholic fatty liver disease. QJM (2009) 2.50
Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology (2010) 2.50
Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol (2013) 2.50
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2009) 2.42
Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut (2005) 2.39
The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications. J Gastroenterol (2014) 2.32
Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2010) 2.28
Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer (2007) 2.23
Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer (2009) 2.19
Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol (2008) 2.17
Steatosis in chronic hepatitis C: why does it really matter? Gut (2006) 2.10
Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology (2010) 2.09
The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology (2008) 2.04
Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia (2009) 2.03
Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr (2009) 1.98
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2006) 1.86
Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol (2010) 1.75
Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology (2008) 1.74
Hypertransaminasemia in childhood as a marker of genetic liver disorders. J Gastroenterol (2005) 1.71
Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med (2012) 1.71
Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol (2014) 1.69
The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol (2009) 1.67
Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol (2007) 1.65
Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol (2009) 1.64
Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity (Silver Spring) (2008) 1.64
Treatment of non-alcoholic fatty liver disease. Postgrad Med J (2006) 1.63
Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol (2006) 1.63
Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol (2007) 1.61
Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes. World J Gastroenterol (2008) 1.59
Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2008) 1.54
Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem (2011) 1.53
Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol (2007) 1.50
Hepatobiliary function assessed by 99mTc-mebrofenin cholescintigraphy in the evaluation of severity of steatosis in a rat model. Eur J Nucl Med Mol Imaging (2006) 1.50
Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol (2011) 1.48
Steatosis as a risk factor in liver surgery. Ann Surg (2007) 1.48
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2006) 1.47
Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care (2011) 1.46
Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J Clin Invest (2012) 1.45
Association Between Endogenous Sex Hormones and Liver Fat in a Multiethnic Study of Atherosclerosis. Clin Gastroenterol Hepatol (2015) 1.45
Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2013) 1.44
Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS One (2010) 1.44
Disruption of protein kinase A in mice enhances healthy aging. PLoS One (2009) 1.43
Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing Th17 responses in mice and patients. Diabetes (2012) 1.42
Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res (2011) 1.42
The peroxisome: still a mysterious organelle. Histochem Cell Biol (2008) 1.41
Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol (2011) 1.41
Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis. Am J Pathol (2009) 1.41
Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis. Mol Metab (2016) 1.40
Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care (2010) 1.40
Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci (2003) 1.37
PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. J Nutr (2011) 1.34
Liver diseases and metabolic syndrome. J Gastroenterol (2008) 1.33
Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids. Hepatology (2009) 1.32
Common genetic variations in CLOCK transcription factor are associated with nonalcoholic fatty liver disease. World J Gastroenterol (2007) 1.31
Think small: zebrafish as a model system of human pathology. J Biomed Biotechnol (2012) 1.30
Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes (2008) 1.30
Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut (2005) 1.30
Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol (2005) 1.30
Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol (2010) 1.29
Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr (2011) 1.29
Macrophage content in subcutaneous adipose tissue: associations with adiposity, age, inflammatory markers, and whole-body insulin action in healthy Pima Indians. Diabetes (2008) 1.29
Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol (2012) 1.27
Fructose as a key player in the development of fatty liver disease. World J Gastroenterol (2013) 1.26
Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology (2009) 1.26
Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes (2008) 1.24
Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation. J Lipids (2011) 1.23
Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J Gastroenterol (2008) 1.22
Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs (2009) 1.21
Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort. AIDS (2013) 1.21
Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2011) 1.21
Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. World J Gastroenterol (2006) 1.21
High serum uric acid increases the risk for nonalcoholic Fatty liver disease: a prospective observational study. PLoS One (2010) 1.19
Treatment of non-alcoholic fatty liver disease. Ther Clin Risk Manag (2007) 1.18
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology (2009) 1.18
Weight control and prevention of metabolic syndrome by green tea. Pharmacol Res (2010) 1.15
Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut (2006) 1.15
N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis. J Nutr (2008) 1.15
Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study. Ann Rheum Dis (2006) 1.15
Prevalence of Non-Alcoholic Fatty Liver Disease and Its Predictors in North of Iran. Iran J Public Health (2014) 1.14
Improving glucose metabolism with resveratrol in a swine model of metabolic syndrome through alteration of signaling pathways in the liver and skeletal muscle. Arch Surg (2011) 1.14
Fat: a matter of disturbance for the immune system. World J Gastroenterol (2010) 1.13
Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats. PLoS One (2011) 1.13
The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. BMC Med (2009) 1.12
Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease. ISRN Gastroenterol (2011) 1.12
Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials. Clin Gastroenterol Hepatol (2008) 1.11
Liver biopsy. Hepatology (2009) 7.61
Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol (2012) 2.89
Endoscopic cyanoacrylate versus transjugular intrahepatic portosystemic shunt for gastric variceal bleeding: a single-center U.S. analysis. Gastrointest Endosc (2009) 2.63
Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol (2010) 2.41
Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis (2009) 2.22
Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med (2007) 2.17
Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol (2009) 2.06
Bleeding and thrombosis in cirrhotic patients: what really matters? Dig Liver Dis (2011) 1.54
Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation? J Clin Gastroenterol (2009) 1.47
Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding. Liver Int (2013) 1.47
Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant. Transpl Int (2011) 1.46
Intermittent disconjugate gaze: a novel finding in nonalcoholic steatohepatitis and cryptogenic cirrhosis. Hepatology (2005) 1.39
Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol (2006) 1.27
Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci (2014) 1.27
Coagulation in liver disease: a guide for the clinician. Clin Gastroenterol Hepatol (2013) 1.24
Expression of perilipin and adipophilin in nonalcoholic fatty liver disease; relevance to oxidative injury and hepatocyte ballooning. J Atheroscler Thromb (2009) 1.02
Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol Res (2008) 1.02
The zonal distribution of megamitochondria with crystalline inclusions in nonalcoholic steatohepatitis. Hepatology (2004) 1.00
A rodent model of NASH with cirrhosis, oval cell proliferation and hepatocellular carcinoma. J Hepatol (2008) 0.98
Medical and endoscopic management of gastric varices. Semin Intervent Radiol (2011) 0.97
Statins in liver disease: a molehill, an iceberg, or neither? Hepatology (2008) 0.96
Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl (2003) 0.95
Bleeding gastric varices obliteration with balloon-occluded retrograde transvenous obliteration using sodium tetradecyl sulfate foam. J Vasc Interv Radiol (2011) 0.95
Therapy of NAFLD: antioxidants and cytoprotective agents. J Clin Gastroenterol (2006) 0.93
N-2-butyl-cyanoacrylate for bleeding gastric varices: a United States pilot study and cost analysis. Am J Gastroenterol (2003) 0.93
A clinical survey of bleeding, thrombosis, and blood product use in decompensated cirrhosis patients. Ann Hepatol (2012) 0.91
Treatment of hepatitis C virus infection. Ann Intern Med (2015) 0.91
Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series. Postgrad Med (2015) 0.89
Treatment of primary liver tumors with Yttrium-90 microspheres (TheraSphere) in high risk patients: analysis of survival and toxicities. Technol Cancer Res Treat (2009) 0.88
The role of anti-fibrinolytics, rFVIIa and other pro-coagulants: prophylactic versus rescue? Clin Liver Dis (2009) 0.88
Peripheral platelet count correlates with liver atrophy and predicts long-term mortality on the liver transplant waiting list. Transpl Int (2013) 0.87
Does external beam radiation therapy improve survival following transarterial chemoembolization for unresectable hepatocellular carcinoma? Gastrointest Cancer Res (2012) 0.85
Enlarged hepatocytes in NAFLD examined with osmium fixation: does microsteatosis underlie cellular ballooning in NASH? Am J Gastroenterol (2006) 0.84
Pre- and post-balloon-occluded retrograde transvenous obliteration clinical evaluation, management, and imaging: indications, management protocols, and follow-up. Tech Vasc Interv Radiol (2012) 0.83
Balloon-occluded Retrograde Transvenous Obliteration (BRTO): Preprocedural Evaluation and Imaging. Semin Intervent Radiol (2011) 0.83
The role of recombinant factor VIIa in liver transplantation. Liver Transpl (2005) 0.82
Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease: mechanisms, human evidence, therapeutic implications, and preventive implications. Semin Liver Dis (2012) 0.80
Severe prolongation of the INR in spur cell anemia of cirrhosis: true-true and related? Dig Dis Sci (2006) 0.80
Yo jyo hen shi ko, a novel Chinese herbal, prevents nonalcoholic steatohepatitis in ob/ob mice fed a high fat or methionine-choline-deficient diet. Liver Int (2007) 0.79
Treating thrombosis in cirrhosis patients with new oral agents: ready or not? Hepatology (2014) 0.78
Correction of hemostatic abnormalities and portal pressure variations in patients with cirrhosis. Hepatology (2014) 0.76
Effects of restoring portal flow with anticoagulation and partial splenorenal shunt embolization. Hepatology (2014) 0.76
New concepts of coagulation and bleeding in liver disease. Intern Emerg Med (2010) 0.76
Propensity for non-alcoholic fatty liver disease: more evidence for ethnic susceptibility. Liver Int (2009) 0.75
Divergent effects of peroxisome proliferator-activated receptor-gamma ligands in human and mouse nonalcoholic steatohepatitis. Hepatology (2007) 0.75
Treatment of bleeding gastric varices. J Gastroenterol Hepatol (2005) 0.75
How useful is epsilon-aminocaproic acid for the treatment of hyperfibrinolysis in patients with cirrhosis? Nat Clin Pract Gastroenterol Hepatol (2006) 0.75
Liver invasion of the duodenum due to hepatocellular carcinoma. Clin Gastroenterol Hepatol (2012) 0.75
The liver and statin drug therapy: uncertain navigation in the sea of risk-benefit. Pharmacoepidemiol Drug Saf (2003) 0.75
Nonalcoholic fatty liver disease, portal vein thrombosis and coagulation: more questions than answers? Transplantation (2017) 0.75
Creation of a transjugular intrahepatic portosystemic shunt with use of a preexisting portal-hepatic vein fistula as an alternative route. J Vasc Interv Radiol (2005) 0.75